D-0471-2026 Class II Ongoing
FDA drug recall D-0471-2026 was initiated by PAYLESS COMPOUNDERS, LLC on Mar 6, 2026 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is ongoing. Affected quantity: 91 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 22, 2026
- Initiation Date
- Mar 6, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 91 vials
Product description
Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR
Reason for recall
Lack of Assurance of Sterility
Distribution pattern
OR
Code information
Lot Number 01-27-2026@14S.5
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0471-2026
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026